Allogene (NASDAQ: ALLO) SVP sale covers RSU taxes, holds 124,517 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Allogene Therapeutics SVP of Finance Annie Yoshiyama reported a small share sale mainly for tax purposes. She sold 9,586 shares of common stock in an open-market transaction to cover tax withholding obligations tied to the vesting of restricted stock units under a mandated “sell to cover” arrangement, rather than a discretionary trade. The weighted average sale price ranged from $2.31 to $2.33 per share. After this transaction, she directly holds 124,517 Allogene shares, which include 3,781 shares acquired on March 15, 2026 through an employee stock purchase program.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 9,586 shares ($22,144)
Net Sell
1 txn
Insider
Yoshiyama Annie
Role
SVP, Finance
Sold
9,586 shs ($22K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 9,586 | $2.31 | $22K |
Holdings After Transaction:
Common Stock — 124,517 shares (Direct, null)
Footnotes (1)
- Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $2.31 to $2.33, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Includes 3,781 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program.
Key Figures
Shares sold: 9,586 shares
Sale price range: $2.31–$2.33 per share
Shares held after transaction: 124,517 shares
+1 more
4 metrics
Shares sold
9,586 shares
Open-market sale on April 21, 2026 to cover RSU taxes
Sale price range
$2.31–$2.33 per share
Weighted average price for April 21, 2026 transactions
Shares held after transaction
124,517 shares
Direct Allogene common stock ownership following the sale
Recent ESPP acquisition
3,781 shares
Shares acquired March 15, 2026 via employee stock purchase program
Key Terms
sell to cover, restricted stock units, weighted average price, employee stock purchase program
4 terms
sell to cover financial
"require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction"
Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.
restricted stock units financial
"tax withholding obligations in connection with the vesting of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
employee stock purchase program financial
"acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program."
FAQ
What insider transaction did Allogene Therapeutics (ALLO) report for Annie Yoshiyama?
Allogene reported that SVP, Finance Annie Yoshiyama sold 9,586 shares of common stock. The sale was to cover tax withholding obligations from restricted stock unit vesting under a mandated “sell to cover” arrangement, not a discretionary open-market decision.
Was the Allogene (ALLO) insider sale by Annie Yoshiyama a discretionary trade?
The filing states the sale was not discretionary. Shares were sold to cover tax withholding obligations from vesting restricted stock units under Allogene’s equity incentive plan, which requires a “sell to cover” transaction rather than allowing the insider to choose another payment method.
What role do restricted stock units play in the Allogene (ALLO) insider sale?
The transaction relates to restricted stock units (RSUs) vesting for Annie Yoshiyama. When the RSUs vested, tax obligations arose and were satisfied by selling 9,586 shares under the company’s mandated “sell to cover” policy, as described in the Form 4 footnotes.